| Criteria |
WHO (1998, 1999) |
EGIR (1999) |
NCEP ATP III (2001, 2004) |
AACE/ACE (2003) |
IDF (2005) |
IDF & AHA/NHLBI (2009) |
| Required factor |
IGT, IFG or DM type 2, and/or insulin resistance |
Insulin resistance or hyperinsulinemia |
None |
At least one of the specified risk factors (e.g., obesity,
sedentary lifestyle, age>40) |
Central obesity |
None |
|
plus any 2 or more of the following |
plus any 2 of the following |
but any 3 or more of the following |
plus 2 or more of the following |
plus any 2 of the following |
but any 3 or more of the following |
| Additional factors |
| Obesity |
Waist-to-hip ratio |
WC≥94 cm (men) |
WC≥102 cm (men) |
BMI>25 kg/m² or |
|
Elevated WC and |
|
>0.90 (men) |
WC≥80 cm (women) |
WC≥88 cm (women) |
WC>102 cm (men) |
|
country-specific |
|
Waist-to-hip ratio |
|
|
WC>89 cm (women) |
|
definitions as |
|
>0.85 (women) |
|
|
(10-15% lower for |
|
defined by the |
|
and/or BMI |
|
|
non-Caucasians) |
|
IDF and |
|
>30 kg/m² |
|
|
|
|
AHA/NHLBI |
|
|
|
|
|
|
until more data |
|
|
|
|
|
|
are available |
| Triglycerides |
≥150 mg/dL |
>177 mg/dL |
≥150 mg/dL |
>150 mg/dL |
≥150 mg/dL |
≥150 mg/dL |
|
(≥1.7 mmol/L) |
(>2.0 mmol/L) |
(≥1.7 mmol/L) |
|
(≥1.7 mmol/L) |
(≥1.7 mmol/L) |
|
|
|
or on elevated |
|
or on lipid |
(Rx for elevated |
|
and/or |
|
triglycerides Rx |
|
abnormality Rx |
triglycerides is an |
|
|
|
|
|
|
alternate indicator) |
| HDL - |
<35 mg/dL |
<40 mg/dL |
<40 mg/dL |
<40 mg/dL (men) |
< 40 mg/dL |
<40 mg/dL |
| cholesterol |
(<0.9 mmol/L) (men) |
(<1.0 mmol/L) |
(<1.03 mmol/L) (men) |
<50 mg/dL (women) |
(<1.03 mmol/L) |
(<1.0 mmol/L) |
|
<39 mg/dL |
(men and women) |
<50 mg/dL (<1.29 |
|
(men) |
(men) <50 mg/dL |
|
(<1.0 mmol/L) |
or on dyslipidemia Rx |
mmol/L) (women) or |
|
<50 mg/dL |
(<1.3 mmol/L) |
|
(women) |
|
on reduced |
|
(<1.29 mmol/L) |
(women) (Rx for |
|
|
|
HDL-cholesterol Rx |
|
(women) |
reduced |
|
|
|
|
|
or on lipid |
HDL-cholesterol |
|
|
|
|
|
abnormality Rx |
is an alternate |
|
|
|
|
|
|
indicator) |
| Blood |
≥160/90 mm Hg |
≥140/90 mm Hg or |
≥130/85 mm Hg or |
>130/85 mm Hg |
≥130/85 mm Hg |
≥130/85 mm Hg |
| pressure |
(later modified as |
on hypertension Rx |
on hypertension Rx |
|
or on |
(antihypertensive |
|
≥140/90 mm Hg) |
|
|
|
antihypertensive Rx |
Rx in a patient with |
|
|
|
|
|
|
a history of |
|
|
|
|
|
|
hypertension is an |
|
|
|
|
|
|
alternate indicator) |
| Glucose |
IGT, IGF |
IGT or IFG |
≥110 mg/dL |
110-125 mg/dl |
≥100 mg/dL |
≥100 mg/dL |
|
(≥110 mg/dL) |
(≥110 mg/dL) |
(≥6.1 mmol/L) |
|
(≥5.6 mmol/L) |
(≥5.6 mmol/L) |
|
(≥6.1 mmol/L), |
(≥6.1 mmol/L) |
(includes DM) |
|
or previously |
(Rx of elevated |
|
or DM type 2 |
(but not DM) |
(later modified as |
|
diagnosed type |
glucose is an |
|
|
|
≥100 mg/dL) |
|
2 DM |
alternate indicator) |
|
|
|
(≥5.6 mmol/L) or on |
|
|
|
|
|
|
elevated glucose Rx |
|
|
|
| Other |
Microalbuminuria |
|
|
|
|
|
|
(urinary albumin |
|
|
|
|
|
|
excretion rate |
|
|
|
|
|
|
≥20 μg/min or |
|
|
|
|
|
|
albumin: creatinine |
|
|
|
|
|
|
ratio ≥20 mg/g) (later |
|
|
|
|
|
|
modified as ≥30 |
|
|
|
|
|
|
mg/g) |
|
|
|
|
|
| WHO: World Health Organization; EGIR: European Group for the
Study of Insulin Resistance; NCEP ATP III: National Cholesterol Education
Program Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III); AACE/ACE: American Association
of Clinical Endocrinologists/American College of Endocrinology; IDF: International
Diabetes Federation; AHA/NHLBI: American Heart Association/National Heart,
Lung, and Blood Institute; IGT: impaired glucose tolerance; IFG: impaired
fasting glucose; DM: diabetes mellitus; BMI: body mass index; WC: waist circumference;
Rx: treatment; HDL: high-density lipoprotein. |
